Senior columnist Adam Feuerstein says Pfizer is the next big thing in biotech.
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Any objective look at investing in AAPL has to consider alternatives.
Mason's Maturity; Houston's Problem; Einhorn's Interrogation; Rupert Gets Rocked; Aubrey's Apology.
John Challenger of Challenger Grey & Christmas believes the headwinds are too strong to see job growth like we saw at the beginning of the year.
The top 10 open-market insider purchases and sales filed at the SEC Wednesday.
In a new book, a German wise man recalls how VW shunted Chrysler aside in China.
TheStreet Guest Contributor
Even with trouble lurking at nearly every turn, 401(k) day trading took my precious cargo to the next level.
The Dow tumbles after the government reports that only 115,000 jobs were added in the U.S. last month.
There are many ways for a company to position itself as innovative, but now even job titles are in play.